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Key Points 
 First report demonstrating in vivo elimination of multiple LIC populations from 
 childhood ALL cases using animal models. 
 In vivo models of leukaemia are essential for drug evaluation studies. 
 
Abstract 
Around 20% of children with acute lymphoblastic leukemia (ALL) relapse due to 
failure to eradicate the disease.  Current drug efficacy studies focus on reducing 
leukemia cell burden.  However, if drugs have limited effects on leukemia-initiating 
cells (LIC), these cells may expand and eventually cause relapse.  Parthenolide 
(PTL) has been shown to cause apoptosis of LIC in acute myeloid leukemia.  Here, 
we assessed the effects of PTL on LIC populations in childhood ALL.  Apoptosis 
assays demonstrated that PTL was effective against bulk B- and T-ALL cells, while 
the CD34+/CD19-, CD34+/CD7- and CD34- subpopulations were more resistant.  
However, functional analyses revealed that PTL treatment prevented engraftment of 
multiple LIC populations in NSG mice.  PTL treatment of mice with established 
leukemias from low- and high-risk cases resulted in survival and restoration of normal 
murine hemopoiesis.  In 3 cases only, disease progression was significantly slowed 
in mice engrafted with CD34+/CD19- or CD34+/CD7- and CD34- cells but not 
prevented, demonstrating that individual LIC populations within patients have 
different responses to therapy.  These observations indicate that PTL may have 
therapeutic potential in childhood ALL and provide a basis for developing effective 
therapies that eradicate all LIC populations to prevent disease progression and 
reduce relapse. 
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Introduction 
Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous disease in terms 
of karyotype, immunophenotype and blast morphology.1-3  Several genome-wide 
analyses have described additional genetic changes within individual leukemia 
clones.4-6  Consequently, studies which increase our understanding of the biology 
and evolution of this disease should provide information on leukemogenic pathways 
for therapeutic targeting.  Such studies may help us understand why initial therapies 
can induce remission but some cases then relapse,7-9 especially as many relapses 
occur in the low-risk groups.  
 
ALL cells that can generate leukemias in immune deficient mice, termed leukemia 
initiating cells (LIC), were initially thought to be rare and have a hierarchical 
structure.10-13  Some of these LIC, particularly CD133+/CD19- cells, were resistant to 
treatment with dexamethasone and vincristine,13 commonly used in the induction 
phase of therapy for ALL, so they may survive therapy and eventually cause disease 
relapse.  However, more recent studies using NOD/LtSz-scid IL-2Rc null (NSG) mice 
have revealed that both primitive and more differentiated ALL subpopulations can 
initiate and maintain acute leukemias in this strain.5,14-18  We and others have shown 
that CD34+/CD19+, CD34+/CD19- and CD34- B cell precursor (BCP) ALL 
subpopulations contain LIC.15,18  In childhood T-ALL we found that CD34+/CD7+, 
CD34+/CD7- and CD34- subpopulations had LIC properties.18  Another study 
described CD7+/CD1a- and CD7+/CD1a+ LIC from 1 pediatric and 2 adult T-ALL 
cases19 and a study of mature/cortical T-ALL found LIC in both CD34+/CD7+ and 
CD34-/CD7+ populations.20  The in vivo repopulating capacity has been shown to 
vary depending on the immunophenotype18 and genotype of the LIC.5  These 
findings demonstrate that LIC are more abundant than earlier studies suggested and 
indicate that leukemia evolution may have a branching structure rather than a 
hierarchical one.  This has significant implications for therapy of leukemias.  
Elimination of the population, which contains the greatest proportion of LIC, or has 
the greatest self–renewal potential may just lead to another LIC population evolving 
and expanding to maintain the disease.  Consequently, it will be important to develop 
therapies that can eliminate all populations with LIC potential to prevent further 
evolution and recurrence.  The challenge is to find a way to specifically target LIC 
without causing toxicity to normal cells. 
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Parthenolide (PTL) has been recently investigated as a potential chemotherapeutic 
agent for acute myeloid leukemia (AML) and chronic lymphocytic leukemia.21-26  PTL 
is a naturally occurring sesquiterpene lactone used in the treatment of fever, 
migraines, rheumatoid arthritis and as an anti-inflammatory agent.27-29  PTL can 
induce apoptosis through a range of responses, such as inhibition of nuclear factor 
molecule kappa B (NF-κB), p53 activation and increase of reactive oxygen 
species.21,23  PTL and DMAPT, an analog of PTL, have been shown to be effective in 
AML while sparing normal hemopoietic stem cells (HSC).21,22  PTL can induce 
apoptosis in primary B-ALL cells22 and cell lines.30,31  To date there are no reports on 
the effects of PTL on LIC populations in pediatric ALL.  The aim of this study was to 
evaluate the effects of PTL on childhood ALL cells, especially subpopulations that 
have LIC activity, including those that have been shown to be resistant to current 
therapeutic agents.13 
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Methods 
Patient cells 
Bone marrow (BM) cells from children (median age, 6 years 8 months; range, 6 
months - 19 years) with BCP ALL and T-ALL at presentation or relapse were 
collected with approval of University Hospitals Bristol NHS Trust.  Detailed 
characteristics of the patient samples are shown in Table 1.  Samples were selected 
on the basis of availability of material for study only.  Normal BM (NBM) and 
peripheral blood (PB) samples were obtained from consented healthy donors.  Cells 
were separated using Ficoll-Hypaque (Sigma-Aldrich, Poole, UK), mononuclear cells 
(MNC) were suspended in Iscoves modified Dulbeccos medium (IMDM; Invitrogen, 
Paisley, UK) with 90% fetal calf serum (FCS; Invitrogen) and 10% dimethyl sulfoxide 
(DMSO; Manor Park Pharmaceuticals, Bristol, UK) and stored in liquid nitrogen.  
Mean viability of samples on thawing was 83±17% for ALL samples and 71±17% for 
normal samples. 
 
Cell sorting 
B-ALL cells were stained with antibodies against CD34 (clone 8G12) and CD19 
(clone 4G7).  T-ALL cells were stained with anti-CD34 and anti-CD7 (clone M-T701).  
Normal BM and PB samples were stained with anti-CD34 and anti-CD38 (clone 
HB7).  IgG1 antibodies were used as isotype controls (all BD Biosciences, Oxford, 
UK).  Cells were sorted using a Becton Dickinson Influx Cell sorter (BD Biosciences), 
using Spigot 6.1.9 software, on the basis of fluorescence intensity after gating on 7-
aminoactinomycin D (7AAD; Sigma-Aldrich) negative cells with low forward and side 
scatter.  Details of the proportions of nucleated cells in the sorted populations are 
provided in Supplemental Table 1.  Sorting was performed using the maximum purity 
setting and the purity of sorted subfractions from each sample was checked during 
and after sorting.   
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Table 1 Patient characteristics 
 Patient Subtype Karyotype Age at 
diagnosis 
Sex Disease 
status at 
biopsy 
MRD† 
Risk 
Status 
 1  c-ALL  46XX 5 F Diagnosis  ND 
 2  c-ALL  46XY 6 M Diagnosis  ND 
 3  pre-B  t(4;11), +X 0.6 M Diagnosis  ND 
 4  pre-B  -9 7 F Diagnosis  High 
 5  c-ALL t(12;21), -3, -6, +10 5 F Diagnosis  Low 
 6  pro-B  t(4;11) 0.5 F Relapse  High 
 7  pre-B*  +21, +22 3 M Diagnosis  Low 
 8  c-ALL  -12p 15 M Diagnosis  High 
 9  c-ALL  t(12;21), -12p 6 M Diagnosis  IM 
 10  c-ALL  t(12;21) 6 M Diagnosis  Low 
 11  c-ALL  t(8;21), +9 19 F Relapse  High 
 12  pre-B  Complex 14 M Diagnosis  Low 
 13  c-ALL  46XX 4 F Diagnosis  Low 
 14  pro-B  t(12;17) 14 F Diagnosis  High 
 15  c-ALL  t(12;21) 4 F Diagnosis  Low 
 16  c-ALL  Hyperdiploid 3 F Diagnosis  Low 
 17  pro-B  t(4;11) 0.8 F Diagnosis  High 
 18  c-ALL  i(9), del(9) 16 M Relapse  Low 
 19  c-ALL +7, +9, -12, (iAMP21)  8 F Diagnosis  High 
 20  c-ALL  +3 14 F Diagnosis  High 
 21  pre-B  t(12;21) 8 F Diagnosis  High 
 22  pre-B  Hyperdiploid 3 M Relapse  Low 
 23  pre-B  del 1 2 F Diagnosis  Low 
 24  pre-B  Hyperdiploid 2 M Diagnosis  Low 
 25  pre-B  +14 2 F Diagnosis  Low 
 26  pre-B  t(1;19) 14 M Diagnosis  Low 
 27  pre-B  t(9;22) 15 M Diagnosis  Low 
 28  pre-B  46XY 9 M Diagnosis  High 
 29  T-ALL  +4, +9 15 M Diagnosis  High 
 30  T-ALL  t(11;14) 2 M Relapse  Low 
 31  T-ALL  -9p, +9q 6 M Diagnosis  High 
 32  T-ALL  +7, -9, t(9;16) 5 M Diagnosis  High 
 33  T-ALL  t(1;14), -6 10 M Diagnosis  Low 
 34  T-ALL  46XY 14 M Diagnosis  High 
 35  T-ALL  t(6;7) 1 M Diagnosis  High 
 36  T-ALL  -6 15 M Diagnosis  High 
 37  T-ALL  46XY 13 M Diagnosis  High 
*ALL secondary to Downs syndrome; † MRD risk status at day 28; IM, intermediate; 
ND, not determined 
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In vivo studies 
NSG mice were bred and maintained at the University of Bristol Animal Service Unit.  
Mice were not preconditioned prior to inoculation.  Cells were resuspended in 0.3mL 
IMDM + 5% HAS and injected into the lateral tail veins of 6-8 week old mice.  
Unsorted cells and sorted cell populations were inoculated at a range of doses to 
obtain estimates of LIC frequency in each subpopulation.  
 
In ex vivo drug sensitivity assays, unsorted cells and sorted subpopulations, from 
ALL patients and normal donors, were treated with either PTL for 20 to 24 hours or 
DMSO + phosphate buffered saline (PBS; Invitrogen), as controls, prior to 
inoculation.  
 
In survival assays, mice were inoculated with bulk ALL cells and sorted 
subpopulations.  Mice were monitored weekly for the presence of human cells in PB 
aspirates.  Once the level of human cells was ≥5%, animals were given daily 
intravenous doses of PTL (40mg/kg) or placebo (DMSO+PBS) for 9 days.22,32 
 
In all assays, animals were monitored weekly for the presence of human cells, 
maintained for up to 20 weeks and killed electively or until they began to exhibit 
clinical symptoms of disease.  The gross anatomy was inspected and femoral BM 
samples were removed for flow cytometric and cytogenetic/histologic analyses.  
Immunophenotypes of xenografts were examined using antibodies against human 
CD3, CD10, CD19, CD7, CD33, CD34, CD45 and murine CD45 (all BD Biosciences).  
Cytogenetic analysis by FISH was performed by Bristol Genetics Laboratory, 
Southmead Hospital, Bristol. 
 
Cells harvested from BM of some engrafted mice were used for serial transplantation 
experiments.  For comparison with primary transplants, equal numbers of human 
CD45 cells were inoculated into serial recipients.  These cells were not enriched for 
any particular phenotype before evaluation in sequential xenografts. 
 
In vitro drug sensitivity 
Unsorted ALL cells and sorted subpopulations were co-cultured with increasing 
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concentrations of PTL (Sigma-Aldrich) for 20 to 24 hours in RPMI-1640 (Sigma-
Aldrich) containing 10% FCS and 1% L-glutamine (Invitrogen).  Unsorted and (HSC)-
enriched (CD34+/CD38-) NBM samples were also co-cultured with the drug.  
Apoptosis and viability were assessed by flow cytometry using annexin V-FITC and 
propidium iodide (arcus biologicals, Modena, Italy). 
 
Western blotting and confocal microscopy  
Cells for Western blotting were prepared by the method described by Foka et al.33  
Full details are provided in the Supplemental data. 
 
Statistical analysis 
LIC frequencies were determined by Poisson statistics using L-Calc software 
(StemCell Technologies Inc).  Analysis of variance, followed by Tukey’s post-hoc 
testing, was used to compare drug responses between ≥3 populations.  Matched 
paired T-tests were used to compare viability and engraftment levels between 
untreated and drug-treated groups.  T-tests assuming unequal variance were used to 
compare drug-treated ALL populations with treated HSC.  Data from survival assays 
were analyzed using the log-rank test of survival distribution after treatment.   
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Results 
 
LIC frequency in ALL subpopulations 
Cells from 15 cases were sorted based on expression of CD34 and CD19 (B-ALL 
cases, Fig. 1A) and CD34 and CD7 (T-ALL cases, Fig. 1B).  Cells were inoculated at 
a range of doses to give an estimate of the frequency of LIC (Table 2).  LIC 
frequency in sorted subpopulations varied from 1 in 700 to 1 in 9x105 but was highest 
in CD34+/CD19- cells in B-ALL cases and CD34+/CD7- cells in T-ALL cases.  As the 
number of sorted cells available limited the extent of the dilution analysis, these 
results are likely to be an underestimate of LIC frequencies.  Since LIC were readily 
detectable in all sorted subfractions, we subsequently assessed the effects on PTL 
on these subpopulations.  
 
Table 2 Frequency of LIC in ALL subpopulations 
 
Patient ID  Subpopulation  
 Unsorted CD34+/CD19+ CD34+/CD19- CD34- 
 2 1 / 4x104 1 / 2x105 1 / 3x103 1 / 2x105 
 6     < 1 / 1x106 1 / 4x105  < 1 / 2x103 1 / 1x104 
 16 1 / 2x105 1 / 2x105 1 / 8x103 1 / 3x105 
 17 1 / 9x104 1 / 4x105 1 / 8x102 1 / 5x105 
 20 1 / 5x104 1 / 9x104  < 1 / 1x103 1 / 3x105 
 22 1 / 2x104 1 / 7x104 1 / 9x102 1 / 9x104 
 23 1 / 7x105 0 1 / 9x103 0 
 28 1 / 7x103  < 1 / 8x104 1 / 7x102 1 / 1x105 
Cell Dose 5x103 - 1x107 8x104 - 2x106 8x102 - 1x105 8x104 - 2x106 
     
 Unsorted CD34+/CD7+ CD34+/CD7- CD34- 
 29 1 / 2x105 1 / 2x104 1 / 2x103 1 / 3x104 
 30 1 / 9x103 1 / 6x103 1 / 2x103 1 / 2x104 
 31 1 / 6x105 1 / 8x103 1 / 3x103 - 
 32 1 / 2x105 1 / 9x103 1 / 7x102 1 / 5x105 
 34 1 / 2x104 1 / 9x104  < 1 / 9x102 1 / 3x104 
 35 1 / 9x104 1 / 6x104 1 / 1x103 1 / 1x104 
 36 1 / 1x105 1 / 9x105 1 / 5x103 1 / 9x104 
Cell Dose 5x103 - 5x106 4x103 - 5x106 2x102 - 5x105 5x103 - 5x106 
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Viability of PTL-treated ALL cells  
PTL was initially tested in vitro at a dose range from 0.5-10µM (Fig. 2A) in 10 cases.  
The IC50 was reached at 7.5µM in 9 cases but 10µM PTL reduced the viability of all 
cases to ≤43.3%.  This higher dose had no effect on the viability of normal HSC 
(p=0.91, Fig. 2B).  Therefore, 10µM PTL was used routinely thereafter to maximize 
effects in all patients.   
 
Unsorted cells from 16 of 23 B-ALL cases responded to the drug (<38% viable), 4 
showed a partial response (58-71%) and 3 were largely unaffected (>87% viable).  
There was a significant reduction in viability in all populations following treatment, 
compared to untreated controls (P≤0.043).  When individual subpopulations were 
compared, CD34+/CD19- cells were least affected with 81.3±36% surviving 
(P=0.0005, F=6.64, Fcrit=2.71).  Less than 42±40% cells from unsorted samples or 
other subpopulations remained viable after treatment.  Individual results are shown in 
Supplemental Table 2. 
 
When B-ALL cases were grouped according to MRD risk status, where available, into 
low (n=12) and high risk (n=8), a similar response pattern was observed in the low 
risk group (Fig 3A), with CD34+/CD19- cells most resistant (87.6±26% viable, 
P=0.0001, F=11.31, Fcrit=2.82).  The viability of the other subpopulations was 
≤35±33%, significantly lower than HSC (10014% viable, p≤0.0004).  In the high-risk 
group, there was no significant difference in viability between the sorted 
subpopulations (P=0.53, F=0.75, Fcrit=2.90).  High-risk cases were less responsive 
and CD34+/CD19- and CD34- subpopulations were most resistant (71.3±45% and 
70.3±51% viable, respectively).  These responses were not significantly different 
from results obtained with HSC (0.12<P<0.43).  However, the viability of treated 
unsorted and CD34+/CD19+ cells was significantly lower than treated HSC (P≤0.013). 
 
The effect of PTL was also investigated in B-ALL subpopulations using CD133 (Fig. 
3C, Supplemental Table 3).  CD133+/CD19+ and CD133+/CD19- subpopulations from 
2 patients used above (pts 8, 15) and 4 additional cases (pts 4, 5, 9, 18) were sorted 
and treated with 10µM PTL.  In this cohort, a greater response to PTL was observed 
using unsorted cells (13.7±17% viable) compared to the larger cohort used above 
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and only 5.9±5% CD133+/CD19+ cells survived.  PTL had a reduced effect on the 
CD133+/CD19- subpopulation (71.6±21% viable) compared to the other populations 
assayed (P=0.0002, F=20.91, Fcrit=4.10), but this was significantly reduced compared 
to results from HSC (P=0.032).  
 
Seven of 9 T-ALL cases were affected by PTL (<36% viable) and a partial response 
was observed in the 2 remaining cases (62-69% viable, Fig. 3D).  Only 27.2±27% 
unsorted T-ALL cells survived treatment while 48.4±29% CD34+/CD7+ cells, 
54.9±41% CD34+/CD7- cells and 57.8±74% CD34- cells remained viable (P=0.53, 
F=0.76, Fcrit=3.01).  When treated populations were compared with their untreated 
counterparts there was a significant reduction in the viability in all populations 
(P≤0.039), except CD34- cells (P=0.105).  This less marked effect of PTL on CD34- 
cells was largely attributable to 2 cases where these cells were unaffected by PTL, 
while in the remaining cases <16% CD34- cells survived (P=0.04 cf. untreated).  The 
proportions of unsorted, CD34+/CD7+ and CD34+/CD7- T-ALL cells surviving PTL 
treatment were significantly reduced compared to HSC (P≤0.018).  
 
In vivo engrafting capacity of PTL-treated cells  
Unsorted cells and sorted subpopulations from 5 B-ALL cases and 5 T-ALL cases 
were treated with 10µM PTL for 20-24 hours prior to inoculation to assess whether 
PTL had any effects on the ability of cells to engraft NSG mice (Fig. 4A).  Groups of 
2-4 mice were inoculated with each population assayed.  Cell doses which had 
previously resulted in good engraftment levels were used.  The number of sorted 
cells inoculated varied due to phenotypically primitive cells representing only small 
proportions of the total leukemia blast population (Supplemental Table 1) and 
different immunophenotypes amongst patients.  Treatment of unsorted, 
CD34+/CD19+ and CD34- B-ALL cells with PTL prior to inoculation completely 
prevented engraftment in every case (Fig. 4B).  PTL treatment of CD34+/CD19- cells 
significantly reduced or prevented engraftment in 3 cases (pts 17, 22 & 28).  In the 
other 2 cases, the engrafting capacity of CD34+/CD19- cells from patient 20 was 
unaffected and engraftment was higher in mice inoculated with PTL-treated cells 
from patient 6 (98±3%) than with untreated cells (76±12%, Supplemental Fig. 1).  
FISH analyses on cells recovered from mice engrafted with unsorted and all sorted 
subpopulations, confirmed these cells had the same karyotype as the patients at 
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diagnosis (91-100% FISH+).  Likewise, cells recovered from animals engrafted with 
PTL-treated CD34+/CD19- cells from pts 6 and 20 carried the patient specific 
aberrations (95-100% FISH+).   
 
Treatment with PTL completely prevented engraftment of unsorted T-ALL cells in 4 of 
5 cases (Fig. 4C).  In the remaining case (pt 32) engraftment was significantly 
reduced to 22±6% compared to untreated cells (77±9%, P<0.001).  No engraftment 
was observed using PTL-treated CD34+/CD7+ and CD34- cells.  In 3 cases PTL 
prevented engraftment of CD34+/CD7- cells and significantly reduced engraftment in 
2 cases, from 98±3% to 15±4% (pt 30) and from 52±7% to 16±4% (pt 32), P<0.001.  
FISH analyses confirmed the engrafted cells had an aberrant karyotype (67-100% 
FISH+).  PTL treatment of normal CD34+/CD38- HSC prior to inoculation did not have 
any detrimental effects on the functional capacity of these cells.  Engraftment levels 
of treated cells were 120% relative to the untreated controls (P=0.25, Supplemental 
Fig. 2). 
 
Self-renewal capacity of resistant cells 
In the 3 cases where in vitro PTL treatment of LIC had little (CD34+/CD19-, pts 6, 20) 
or limited effects (CD34+/CD7-, pt 32) on engrafting capacity, cells recovered from 
murine BM were transplanted into secondary animals to assess the self-renewal 
ability of the PTL-treated cells (Supplemental Table 4).  Cells were not re-sorted prior 
to inoculation into secondary recipients but they received equivalent numbers of 
human cells as their primary counterparts.  Comparable levels of engraftment were 
observed in the primary and secondary recipients.  Inoculated LIC differentiated in 
vivo to give rise to leukemias that were typical of the patient samples at biopsy.  
However, a proportion of the grafts from animals inoculated with PTL-treated or 
untreated CD34+/CD19- cells remained CD34+/CD19- (3.7±0.6%).  Likewise, the 
majority of cells recovered from mice inoculated with treated or untreated 
CD34+/CD7- cells were CD34+/CD7+ but 14.2±2.3% remained CD34+/CD7-, indicating 
self-renewal of these primitive LIC. 
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In vivo activity of PTL in NSG 
Unsorted and sorted cell populations from 9 cases were inoculated into NSG and 
PTL was administered when leukemia was established in the mice (Fig 5A).  Disease 
progression was prevented in PTL-treated animals, while the leukemia burden in 
placebo-treated animals continued to rise until they had all succumbed to disease 
within 9 weeks after treatment commenced.  PTL significantly increased survival for 
each treated xenograft (P<0.0014, Fig. 5B & C).  The median survival time of 
untreated mice was 29 days (range 2-60) after treatment commenced for those 
engrafted with sorted and unsorted B-ALL cells and 25 days (range 6-36) for T-ALL 
xenografts.  Disease progression continued in only 4 PTL-treated xenografts: a 
CD34+/CD19- xenograft of pt 6 survived for 24 days after treatment commenced, 
untreated counterparts survived only 2 days.  Treated CD34+/CD7- and CD34- 
xenografts from pt 32 survived 48 days and 46 days, respectively, while the 
untreated animals survived 25 and 6 days, respectively.  One CD34- xenograft from 
pt 30 survived for 34 days; however, the untreated equivalents succumbed at day 17.  
Xenografts of pt 30 had high levels of leukemia prior to treatment (24.2-65.8%).  
Following treatment, the levels of human cells detected in treated mice decreased, 
with the exception of 1 CD34- xenograft noted above, and levels of murine 
hemopoietic cells increased (Supplemental Fig. 3).  The leukemia burden continued 
to increase in untreated animals and they all had to be killed between 2-36 days from 
treatment commencing.  All other treated xenografts were disease-free when 
electively killed up to 18 weeks from commencement of treatment.  PTL significantly 
decreased the leukemia cell burden in all treated animals (P<0.002, Fig. 5D & E).  
With the exception of the 4 xenografts noted above, the majority of cells recovered 
from PTL-treated animals expressed murine CD45.  A representative example of 
immunophenotypic analyses of BM cells from untreated and PTL-treated xenografts 
established with CD34+/CD19- cells from pt 20 is shown in Fig. 5F.  
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Confirmation of activated NF-κB in ALL  
Since PTL is a potent inhibitor of NF-κB, we investigated whether this mechanism of 
action was operational in a cohort of samples, including cases where PTL treatment 
had limited effects.  The effects of the drug on the expression of active and total p65, 
phospho-IκB and IκB in a representative sample are shown in Supplemental Fig. 4.  
In all cases, there was constitutive expression of active p65 and phospho-IκB.  
Following PTL treatment, expression of both molecules was reduced, demonstrating 
inhibition of NF-κB.  Constitutive expression of NF-κB was also confirmed in unsorted 
and sorted subpopulations by confocal microscopy.  Treatment of unsorted samples 
resulted in inhibition of NF-κB.  However, there was no difference in the levels of NF-
κB expression in CD34+/CD19- cells or CD34+/CD7- and CD34- cells from the 
resistant cases.  A representative example (pt 32) is shown in Supplemental Fig. 5. 
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Discussion 
Outcomes for pediatric leukemias are increasingly successful.  Nevertheless, 15-20% 
of patients relapse due to failure to eradicate the disease and most of these patients 
will not survive.  Most drug efficacy studies focus on initial short-term effects, such as 
reducing the overall leukemia cell burden.  However, if drugs have no effect on the 
LIC they may expand and eventually cause relapse.  In this study we determined the 
phenotype of LIC a priori in a cohort of childhood ALL cases from mixed prognostic 
subgroups.  LIC were detected in all sorted subpopulations assessed, in agreement 
with previous reports15,18-20 and were most enriched in the CD34+/CD19- and 
C34+/CD7- subpopulations in B- and T-ALL cases, respectively.  Consequently, we 
assessed the effects of PTL on unsorted cells and on all subpopulations with LIC 
activity.  
 
Apoptosis assays indicated that overall PTL reduced the viability of unsorted B-ALL 
cells to <38% and T-ALL cells to <28%.  Patients who were classified as high risk by 
MRD were less responsive to PTL but an IC50 was reached at 10µM.  At this dose 
PTL had no effect on the viability of CD34+/CD38- HSC.  These findings are in 
agreement with Guzman et al, who reported that 53.5% unsorted B-ALL cells 
survived treatment with PTL.22  However, the effects of in vitro PTL treatment on 
CD34+/CD19-, CD133+/CD19-, CD34+/CD7- and CD34- subpopulations were more 
limited and disappointing compared to the reported effects of PTL and DMAPT in 
AML.21,22  Nevertheless, a limitation of short-term assays is that they only provide a 
snapshot of the value of a drug at a specific time point.  It is crucial to undertake 
functional studies of drug-treated cells to assess efficacy and targeting of specific cell 
populations.   
 
When we assessed the capacity of in vitro PTL-treated subpopulations to repopulate 
NSG mice, engraftment of unsorted and most sorted cell populations was completely 
prevented or significantly reduced.  Interestingly, engraftment of the CD34+/CD19-, 
CD34+/CD7- and CD34- subpopulations was severely impaired or completely 
prevented following PTL treatment, demonstrating that PTL can induce apoptosis in 
phenotypically primitive and more differentiated LIC and prevent disease 
establishment in vivo.  Since we have previously shown that the functional ability of 
primitive LIC populations from patients 6, 13, 14, 16, 17 were unaffected by in vitro 
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treatment with dexamethasone and vincristine,13 the observed reduction in engrafting 
capacity of multiple LIC subpopulations, following PTL treatment, suggests this drug 
may be more effective.  In vitro treatment of CD34+/CD19- cells from 2 B-ALL cases 
and CD34+/CD7- cells from 1 T-ALL case had only limited or no detrimental effects 
on the ability of these cells to engraft NSG mice.  These cells could self-renew to 
repopulate serial NSG and recapitulate the original leukemia phenotype.  Our results 
on the NSG engrafting capacity of in vitro PTL-treated cells are in agreement with 
results in AML.21,22,25  These findings demonstrate that PTL may have more potential 
as a therapeutic agent than the results from our short-term apoptosis assays 
indicated.  
 
To further evaluate therapeutic potential we assessed the activity of PTL in vivo by 
treating animals with established leukemias.  These models more closely mimic the 
clinical setting and disease progression since the leukemia cells disseminate to 
extramedullary organs once the BM is engrafted.  PTL was well tolerated, with no 
toxicity observed and resulted in significant reductions in leukemia burden in the BM 
and extramedullary organs of mice engrafted with unsorted cells and sorted 
subpopulations.  The overall outcome was survival of treated animals with restoration 
of murine hemopoiesis.  Even animals with high leukemia cell burdens (>50% in PB) 
prior to treatment were successfully treated and survived until electively killed.  
Administration of PTL to xenografts established with CD34+/CD19- cells from pt 20 
resulted in elimination of the leukemia and full recovery of murine hemopoiesis.  In 
contrast, in vitro treatment of CD34+/CD19- LIC from this patient prior to inoculation 
into NSG had no effect on the engrafting capacity.  These data highlight the 
importance of conducting drug testing in vivo using xenograft models.   
 
Despite the clear and potent effects of in vivo PTL treatment, specific xenografts from 
3 pts (6, 30, 32) were less responsive to the drug.  Treatment of these xenografts 
significantly prolonged survival and reduced leukemia burden but did not prevent 
progression.  Two were high-risk cases, 2 had relapsed at the time of sampling and 
only 1 is alive at present.  PTL was effective in targeting LIC in other high-risk cases 
and those in relapse, so the lack of response observed in some xenografts cannot be 
attributed to these factors alone.  The survival of all other treated animals and lack of 
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detectable human hemopoiesis, over 120 days after cessation of treatment, is a clear 
indication of the therapeutic potential of PTL. 
 
Taken together these data indicate that PTL is effective against bulk leukemia and all 
LIC populations in the majority of cases studied.  Had we only assessed the effect of 
PTL in vivo on unsorted leukemias, disease progression would have been prevented 
in every case.  However, we have shown that 3 specific subpopulations, with both 
primitive and differentiated phenotypes, from 3 cases were resistant to this drug.  
Furthermore, where possible, we demonstrated PTL did not inhibit the NF-κB 
pathway, one reported mechanism of action,21-24,34 in the resistant LIC in these 
cases, which may be one reason for the observed lack of effect.  Nevertheless, NF-
κB was constitutively active in all unsorted samples analyzed.  This concurs with a 
report that 39 of 42 heterogeneous pediatric ALL samples contained activated NF-κB 
complexes.35  A comprehensive mechanistic investigation of PTL was beyond the 
scope of this study.  It is possible that the 3 resistant cases had more aggressive 
disease and that more intensive therapy would be required to ablate specific LIC in 
these patients.  
 
ALL is currently being treated by a range of drugs, such as glucocorticoids, 
anthracyclines, vinca alkaloids, asparaginase, alkylating agents and 
antimetabolites.36  Despite their different modes and sites of action, most of those 
agents have been shown to induce NF-κB activation which, ironically, is a self-
protective mechanism for the cell.37  Using NF-κB inhibitors in combination with 
chemotherapeutic agents would potentially improve clearance of leukemia cells.  The 
effects of PTL on AML cells can be enhanced when it is used in combination with 
agents such as with mTOR38-42 and PI3K inhibitors.25  Bortezomib, an inhibitor of the 
ubiquitin proteasome pathway has been shown to be active in combination with 
several agents43-45 and act synergistically with the mTOR inhibitor RAD001 to kill ALL 
cells in vitro.46  Therefore, by combining PTL or DMAPT with mTOR/proteasome 
inhibitors it may be possible to achieve greater toxicity to pediatric ALL cells.  It will 
be of interest to investigate such drug combinations in the resistant cases from our 
cohort. 
 
This study represents the first report demonstrating in vivo ablation of multiple LIC 
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populations in childhood ALL.  PTL was not dependent on expression of specific cell 
surface markers and was not restricted to specific subtypes.  The findings add to the 
evidence that some LIC remain resistant to available agents and these cells could 
subsequently cause relapse.  This report also highlights the importance of using 
animal models of leukemia to conduct drug evaluation studies, rather than just short-
term viability analyses.  
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Figure Legends 
Figure 1 Assessment of LIC content of sorted ALL subpopulations 
B-ALL cells from 8 patients (2, 6, 16, 17, 20, 22, 23, 28) were sorted for expression of 
CD34 and CD19 (A) and cells from 7 T-ALL cases (29-32, 34-36) were sorted for 
expression of CD34 and CD7 (B).  Unsorted cells and sorted subpopulations were 
inoculated into NSG mice to evaluate the LIC content.  Two to four mice were 
injected per cell dose.  Each patient is represented by a specific symbol and each 
symbol depicts the leukemia engraftment detected in the BM of an individual mouse. 
 
Figure 2 Response of ALL cells and normal HSC to PTL 
(A) Percentage of viable ALL cells after PTL treatment in 7 B-ALL cases (open 
symbols) and 3 T-ALL cases (closed symbols).  PTL was used at a dose range from 
0.5 to 10µM and viability was assessed at 20 to 24 hours by flow cytometry using 
Annexin V and PI.  Samples depicted with dashed lines are high MRD risk cases.  
(B) Viability of CD34+/CD38- HSC from normal BM treated with PTL (10µM) 
compared to untreated controls (n=6).  
 
Figure 3 Viability of B- and T-ALL populations after PTL exposure 
(A) Low MRD risk (n=12) and (B) high MRD risk (n=8) B-ALL subpopulations were 
sorted using antibodies against CD34 and CD19.  (C) Six cases were sorted using 
antibodies against CD133 and CD19.  Squares represent the low risk cases, 
triangles intermediate risk and circles high-risk cases.  (D) Subpopulations from nine 
T-ALL cases were sorted using antibodies against CD34 and CD7.  Two of the 9 
cases were low MRD risk and are depicted with open squares.  High MRD risk cases 
are depicted with filled circles.  Graphs show the proportion of viable B- and T-ALL 
subpopulations following exposure to 10µM PTL.  Data is expressed as a percentage 
of untreated controls, each symbol represents results from individual patients, 
horizontal bars represent mean viability.  ** P ≤ 0.01, *** P≤0.001. 
 
Figure 4 In vivo propagating ability of PTL-treated ALL subpopulations 
(A) Unsorted and sorted ALL cells were treated with PTL for 20-24 hours in vitro then 
subsequently injected into NSG mice.  Cells were inoculated at the following doses 
per mouse:- unsorted (1-5x106), CD34+/CD19+ (8x104-1x106), CD34+/CD19- 
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(1.8x103-1.2x105), CD34- (1.5-2x106 B-ALL), CD34+/CD7+ (1-1.5x106), CD34+/CD7- 
(4-6x104) and CD34- (1.5-5x106 T-ALL).  After 4-12 weeks, leukemia cell engraftment 
in BM was analyzed by flow cytometry using a panel of antibodies.  (B and C) The 
levels of engraftment attained using unsorted and sorted subpopulations from 5 B-
ALL cases (B) and from 5 T-ALL cases (C).  Each symbol depicts the engraftment 
level of human leukemia cells, from the patients indicated, measured in BM of 
individual mice.  Closed symbols represent mice inoculated with untreated cells, 
opens symbols represent mice inoculated with PTL-treated cells.  Solid horizontal 
bars represent mean engraftment levels using untreated cells.  Dashed bars 
represent mean engraftment levels using PTL-treated cells. 
 
Figure 5 PTL improves the survival of NSG mice engrafted with ALL 
 subpopulations 
(A) NSG mice were transplanted with bulk and sorted subpopulations from B-ALL 
and T-ALL cases.  Once engrafted, mice were treated for 9 days with PTL (40 
mg/kg/day) and monitored thereafter.  (B &C) Kaplan-Meier plots of the survival of 
animals engrafted with B-ALL (B, pts 6, 20, 22, 27, 28) and T-ALL subpopulations (C, 
pts 30, 32, 34, 35).  Time indicated is time from commencement of treatment, day 0. 
The numbers in parentheses signify the numbers of mice used in each group.  (D & 
E) PTL decreases leukemia cell burden in xenografts from B-ALL populations (D) 
and T-ALL populations (E).  The percentage of leukemia cells in the BM of individual 
animals from each inoculated population is shown.  Each symbol represents a 
specific patient.  ** P ≤ 0.01, *** P ≤ 0.001, compared to untreated animals.  (F) Flow 
cytometric analysis of BM from mice engrafted with CD34+/CD19- cells from pt 20.  
Results from an untreated and a treated mouse are shown.  In histograms, grey 
peaks represent murine CD45, black peaks are isotype controls.  Spleens removed 
from the treated mouse (left, PTL) and untreated mouse (right, U). 
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